Member Info for L2analyst

Asking price jumped to 5.90p

We need an rns like redx, and why wouldnt major pharmaceutical companies not make an offer now? Given phase 1 and 2 is first class results!

What's going on here, price is stuck, buys and sells don't make any difference

If you see the interview our CEO they already have the interest of the major pharmaceutical companies and other organisations it was just the regulatory pathway which they are scheduled for meeting, this will move so fast when the rns lands

Looks like from medical point of view it's got the green light! No wonder our director kept saying in next month or two share price will be vastly higher

"A larger phase 3 trial of Flu-v will now go ahead to see if the vaccine can prevent 'real-life flu', rather than only increasing the number of antibodies against flu produced in an individual's body.

It's a must listen to anyone who has missed it

https://www.brrmedia.co.uk/broadcasts/5e677b0f9672d83b987783d4/open-orphan-plc-publication-of-positive-results

GSK stopped after phase 1 but hvivo have met phase 1 and 2, it's a first class vaccine! Only problem was the regulatory pathway and sadly it has to take this Corona virus to speed the pathway, which no doubt would happen now, in that interview I posted earlier they said major pharmaceutical companies already interested it's just that so called regulatory pathway where they are going to have meeting to iron it out, and why is our director so confident that in 2 months time share price will be vastly high and he said giant is awakening

They got lots of interest
For flu-v to take to final stage, just regulatory pathway required now unless your a major pharmaceutical company as its costly then you will not show interest, just my take GSK got to be involved here, listen to the interview

https://www.brrmedia.co.uk/broadcasts/5e677b0f9672d83b987783d4/open-orphan-plc-publication-of-positive-results

Check that buy out, its above asking price

https://www.proactiveinvestors.co.uk/companies/news/914618/open-orphan-joint-venture-s-flu-trial-showcased-in-peer-reviewed-journal-914618.html

Open Orphan joint-venture's flu trial showcased in peer reviewed journal

The article concluded the vaccine is immunogenic (able to produce an immune response) and “merits phase III development to explore efficacy”

The results from a clinical trial of a broad-spectrum flu jab being developed by an Open Orphan PLC (LON:ORPH) joint-venture have been published in a peer-reviewed journal.

The data from the FLU-v 003 IIb study of the FLU-v vaccine appeared in the Annals of Internal Medicine periodical.

The new potential treatment was created by scientists at Imutex, which is 49%-owned by Open Orphan subsidiary hVIVO.

The journal article concluded the vaccine is immunogenic (able to produce an immune response) and “merits phase III development to explore efficacy”.

With a “compelling data package” from two phase II trials, Imutex is scheduling meetings with the US and European regulatory authorities to plot a development pathway for FLU-v, Open Orphan said.

The advantage of FLU-v over the seasonal flu vaccine is its composition, which will remain the same year after year, said chief executive Trevor Phillips.

 As it is manufactured synthetically, it can be made year-round, increasing the number of doses available worldwide, he added.

“It will not be subject to a strict vaccination window as is the case with seasonal flu vaccines,” the Open Orphan CEO explained.

“Also, being a universal vaccine, it should provide protection against new strains of flu virus which the seasonal flu vaccine is not able to do.”

Chairman Cathal Friel said the market potential for a broad-spectrum universal influenza vaccine was “significant”.

He added: “[It] has become increasingly important and valuable in recent weeks when governments around the world are finally waking up and realising that universal flu vaccines need to be commercialised and there must be a better way forward than reliance on the traditional annual flu vaccination process which has variable efficacy, offers little protection against emerging strains and is available in limited quantities.

“A universal flu vaccine can and should be targeted at the entire population base.”

According to our CEO this is a giant awakening, and universal flu-v is a giant no doubt

That's very good news so selling almost finished, also it's crazy to think major pharmaceutical companies like gsk will let go of this flu-v when the results is first class,

"FLU-v is a first-in-class 'universal', broad spectrum, standalone, influenza vaccine candidate "

Even the oillies are up from the lows but we are just going down, ridiculous

Look at ncyt, just selling a test kit they are up from 6p to 187p but we will be selling the challenge model!

First corona virus challenge model and with intererst for flu v, we are below placing price! What a joke

250k buy at 6.20p that's significantly when the price is 6.05

Full price to buy, perhaps seller finished?

Fantastic interview, lots more to come

In one of the interviews he said in 2 .months tome share price will be alot higher, perhaps he can sell flu-v or a deal with major pharmaceutical companies